Candel Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CADL Nasdaq 2836 www.candeltx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Candel Therapeutics, Inc.

Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-Term - Jan 14th, 2026 3:37 am
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025 - Nov 17th, 2025 2:05 pm
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - Nov 13th, 2025 6:25 am
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors - Nov 4th, 2025 7:00 am
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London - Nov 3rd, 2025 6:05 am
Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board - Oct 16th, 2025 6:05 am
Candel Therapeutics announces interim data from phase 1b CAN-3110 trial - Oct 15th, 2025 6:31 am
Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer - Oct 14th, 2025 6:10 am
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc. - Oct 14th, 2025 6:10 am
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine - Oct 14th, 2025 6:05 am
Candel Therapeutics to Present at the SITC 2025 Annual Meeting - Oct 3rd, 2025 7:05 am
Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 - Sep 29th, 2025 6:05 am
Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 - Sep 17th, 2025 6:05 am
Sector Update: Health Care Stocks Decline Late Afternoon - Sep 3rd, 2025 1:52 pm
Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board - Sep 2nd, 2025 6:05 am
Candel Therapeutics to Participate in Upcoming Investor Conferences in September - Aug 28th, 2025 6:05 am
Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights - Aug 14th, 2025 6:05 am
With 44% stake, Candel Therapeutics, Inc. (NASDAQ:CADL) seems to have captured institutional investors' interest - Aug 7th, 2025 6:21 am
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference - Jul 30th, 2025 6:05 am
Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer - Jul 24th, 2025 6:05 am